Skip to main content
Top
Published in: Digestive Diseases and Sciences 6/2018

01-06-2018 | Original Article

Profiles of Patients Who Use Marijuana for Inflammatory Bowel Disease

Authors: Ann Marie Kerlin, Millie Long, Michael Kappelman, Christopher Martin, Robert S. Sandler

Published in: Digestive Diseases and Sciences | Issue 6/2018

Login to get access

Abstract

Background

Marijuana is legal in a number of states for indications that include inflammatory bowel diseases (IBD), and patients are interested in its potential benefits.

Aims

We aimed to describe the legal use of marijuana in individuals with IBD in the USA who participate within the CCFA Partners internet-based cohort.

Methods

A total of 2357 participants who lived in states where prescription or recreational marijuana was legal, were offered the opportunity to complete a survey on marijuana use and IBD symptoms including perceived benefits of therapy. Bivariate statistics and logistic regression models were used to determine factors associated with marijuana use.

Results

Surveys were completed by 1666 participants (71%) with only 214 (12.8%) indicating they had asked their medical doctor about its use and 73 actually using prescribed marijuana (4.4%). Within the respondent group (N = 1666), 234 participants lived where both medical and recreational marijuana is legal and 49 (20.9%) reported recreational marijuana use specifically for IBD. Users reported positive benefits (80.7%), but users also reported more depression, anxiety, pain interference, and lower social satisfaction than non-users. Those prescribed marijuana reported more active disease, and more use of steroids, narcotics, and zolpidem.

Conclusions

Few IBD patients consulted their medical doctors about marijuana use or used prescription marijuana. Where recreational marijuana was available, usage rates were higher. Users reported benefits but also more IBD symptoms, depression, anxiety, and pain. Marijuana use may be higher in patients with IBD symptoms not well treated by conventional medical approaches.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ananthakrishnan A, Kwon J, Raffals L, et al. Variation in treatment of patients with inflammatory bowel diseases at major referral centers in the United States. Clin Gastroenterol Hepatol. 2015;13:1197–1200.CrossRefPubMed Ananthakrishnan A, Kwon J, Raffals L, et al. Variation in treatment of patients with inflammatory bowel diseases at major referral centers in the United States. Clin Gastroenterol Hepatol. 2015;13:1197–1200.CrossRefPubMed
2.
go back to reference Belendiuk K, Baldini L, Bonn-Miller M. Narrative review of the safety and efficacy of marijuana for the treatment of commonly state-approved medical and psychiatric disorders. Addict Sci Clin Pract. 2015;10:1–10.CrossRef Belendiuk K, Baldini L, Bonn-Miller M. Narrative review of the safety and efficacy of marijuana for the treatment of commonly state-approved medical and psychiatric disorders. Addict Sci Clin Pract. 2015;10:1–10.CrossRef
3.
go back to reference Ahmed W, Katz S. Therapeutic use of cannabis in inflammatory bowel disease. Gastroenterol Hepatol. 2016;12:668–679. Ahmed W, Katz S. Therapeutic use of cannabis in inflammatory bowel disease. Gastroenterol Hepatol. 2016;12:668–679.
4.
go back to reference Allegretti J, Courtwright A, Lucci M, Korzenik J, Levine J. Marijuana use patterns among patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:2809–2814.CrossRefPubMedCentral Allegretti J, Courtwright A, Lucci M, Korzenik J, Levine J. Marijuana use patterns among patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:2809–2814.CrossRefPubMedCentral
5.
go back to reference Naftali T, Schleider B, Dotan I, Lansky E, Benjaminov F, Konikoff F. Cannabis induces a clinical response in patients with Crohn’s disease; a prospective placebo-controlled study. Clin Gastroenterol Hepatol. 2013;11:1276–1280.CrossRefPubMed Naftali T, Schleider B, Dotan I, Lansky E, Benjaminov F, Konikoff F. Cannabis induces a clinical response in patients with Crohn’s disease; a prospective placebo-controlled study. Clin Gastroenterol Hepatol. 2013;11:1276–1280.CrossRefPubMed
6.
go back to reference Lal S, Prasad N, Ryan M, et al. Cannabis use amongst patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2011;23:891–896.CrossRefPubMed Lal S, Prasad N, Ryan M, et al. Cannabis use amongst patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2011;23:891–896.CrossRefPubMed
7.
go back to reference Storr M, Devlin S, Kaplan G, Panaccione R, Andrews C. Cannabis use provides symptom relief in patients with inflammatory bowel disease but is associated with worse disease prognosis in patients with Crohn’s disease. Inflamm Bowel Dis. 2014;20:472–480.CrossRefPubMed Storr M, Devlin S, Kaplan G, Panaccione R, Andrews C. Cannabis use provides symptom relief in patients with inflammatory bowel disease but is associated with worse disease prognosis in patients with Crohn’s disease. Inflamm Bowel Dis. 2014;20:472–480.CrossRefPubMed
8.
go back to reference Weiss A, Friedenberg F. Patterns of cannabis use in patients with inflammatory bowel disease: a population based analysis. Drug Alcohol Depend. 2015;156:84–89.CrossRefPubMed Weiss A, Friedenberg F. Patterns of cannabis use in patients with inflammatory bowel disease: a population based analysis. Drug Alcohol Depend. 2015;156:84–89.CrossRefPubMed
9.
go back to reference Long M, Kappelman M, Martin C, et al. Development of an internet-based cohort of patients with inflammatory bowel disease (CCFA partners); Methodology and initial results. Inflamm Bowel Dis. 2012;18:2099–2106.CrossRefPubMed Long M, Kappelman M, Martin C, et al. Development of an internet-based cohort of patients with inflammatory bowel disease (CCFA partners); Methodology and initial results. Inflamm Bowel Dis. 2012;18:2099–2106.CrossRefPubMed
10.
go back to reference Thia K, Faubion W, Loftus E, Persson T, Persson A, Sandborn W. Short CDAI: development and validation of a shortened and simplified Crohn’s disease activity index. Inflamm Bowel Dis. 2011;17:105–111.CrossRefPubMed Thia K, Faubion W, Loftus E, Persson T, Persson A, Sandborn W. Short CDAI: development and validation of a shortened and simplified Crohn’s disease activity index. Inflamm Bowel Dis. 2011;17:105–111.CrossRefPubMed
11.
go back to reference Jowett S, Seal C, Phillips E, Gregory W, Barton J, Welfare M. Defining relapse of ulcerative colitis using a symptom-based activity index. Scand J Gastroenterol. 2003;38:164–171.CrossRefPubMed Jowett S, Seal C, Phillips E, Gregory W, Barton J, Welfare M. Defining relapse of ulcerative colitis using a symptom-based activity index. Scand J Gastroenterol. 2003;38:164–171.CrossRefPubMed
12.
go back to reference Irvine E, Zhou Q, Thompson A. The short inflammatory bowel disease questionnaire; a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT investigators. Canadian Crohn’s Relapse Prevention Trial. Am J Gastroenterol. 1996;91:1571–1578.PubMed Irvine E, Zhou Q, Thompson A. The short inflammatory bowel disease questionnaire; a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT investigators. Canadian Crohn’s Relapse Prevention Trial. Am J Gastroenterol. 1996;91:1571–1578.PubMed
13.
go back to reference Cella D, Yount S, Rothrock N. The patient-reported outcomes measurement information system (PROMIS): progress of an NIIH roadmap cooperative group during tis first two years. Med Care. 2007;45:S3–S11.CrossRefPubMedPubMedCentral Cella D, Yount S, Rothrock N. The patient-reported outcomes measurement information system (PROMIS): progress of an NIIH roadmap cooperative group during tis first two years. Med Care. 2007;45:S3–S11.CrossRefPubMedPubMedCentral
14.
go back to reference Kappelman M, Long M, Martin C, et al. Evaluation of the patient-reported outcomes measurement information system in a large cohort of patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2014;12:1315–1323.CrossRefPubMed Kappelman M, Long M, Martin C, et al. Evaluation of the patient-reported outcomes measurement information system in a large cohort of patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2014;12:1315–1323.CrossRefPubMed
15.
go back to reference Yost K, Eton D, Garcia S, Cella D. Minimally important differences were estimated for six patient-reported outcomes measurement information system-cancer scales in advanced-stage cancer patients. J Clin Epidemiol. 2011;64:507–516.CrossRefPubMedPubMedCentral Yost K, Eton D, Garcia S, Cella D. Minimally important differences were estimated for six patient-reported outcomes measurement information system-cancer scales in advanced-stage cancer patients. J Clin Epidemiol. 2011;64:507–516.CrossRefPubMedPubMedCentral
16.
go back to reference Naftali T, Lev LB, Yablecovitch D, Half E, Konikoff FM. Treatment of Crohn’s disease with cannabis: an observational study. Isr Med Assoc J. 2011;13:455–458.PubMed Naftali T, Lev LB, Yablecovitch D, Half E, Konikoff FM. Treatment of Crohn’s disease with cannabis: an observational study. Isr Med Assoc J. 2011;13:455–458.PubMed
17.
go back to reference de Vries M, van Rijckevorsel D, Vissers K, Wilder-Smith O, van Goor H. Tetrahydrocannabinol does not reduce pain in patients with chronic abdominal pain in a phase 2 placebo-controlled study. Clin Gastroenterol Hepatol. 2017;15:1079–1086.CrossRefPubMed de Vries M, van Rijckevorsel D, Vissers K, Wilder-Smith O, van Goor H. Tetrahydrocannabinol does not reduce pain in patients with chronic abdominal pain in a phase 2 placebo-controlled study. Clin Gastroenterol Hepatol. 2017;15:1079–1086.CrossRefPubMed
18.
go back to reference Massa F, Marsicano G, Hermann H, et al. The endogenous cannabinoid system protects against colonic inflammation. Mucosal Immunol. 2011;4:574–583.CrossRef Massa F, Marsicano G, Hermann H, et al. The endogenous cannabinoid system protects against colonic inflammation. Mucosal Immunol. 2011;4:574–583.CrossRef
19.
go back to reference Borrelli F, Fasolino I, Romano B, et al. Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. Biochem Pharmacol. 2013;85:1306–1316.CrossRefPubMed Borrelli F, Fasolino I, Romano B, et al. Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. Biochem Pharmacol. 2013;85:1306–1316.CrossRefPubMed
20.
go back to reference Borrelli F, Aviello G, Romano B, et al. Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis. J Mol Med. 2009;87:1111–1121.CrossRefPubMed Borrelli F, Aviello G, Romano B, et al. Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis. J Mol Med. 2009;87:1111–1121.CrossRefPubMed
21.
go back to reference Storr M, Keenan C, Zhang H, Patel K, Makriyannis A, Sharkey K. Activation of the cannabinoid 2 receptor (CB2) protects against experimental colitis. Inflamm Bowel Dis. 2009;15:1678–1685.CrossRefPubMedPubMedCentral Storr M, Keenan C, Zhang H, Patel K, Makriyannis A, Sharkey K. Activation of the cannabinoid 2 receptor (CB2) protects against experimental colitis. Inflamm Bowel Dis. 2009;15:1678–1685.CrossRefPubMedPubMedCentral
22.
go back to reference Kunos G, Pacher P. Cannabinoids cool the intestine. Nat Med. 2008;10:678–679.CrossRef Kunos G, Pacher P. Cannabinoids cool the intestine. Nat Med. 2008;10:678–679.CrossRef
23.
go back to reference Wright K, Duncan M, Sharkey K. Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation. Br J Pharmacol. 2008;153:263–270.CrossRefPubMed Wright K, Duncan M, Sharkey K. Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation. Br J Pharmacol. 2008;153:263–270.CrossRefPubMed
24.
go back to reference Izzo A, Sharkey K. Cannabinoids and the gut: new developments and emerging concepts. Pharmacol Ther. 2010;126:21–38.CrossRefPubMed Izzo A, Sharkey K. Cannabinoids and the gut: new developments and emerging concepts. Pharmacol Ther. 2010;126:21–38.CrossRefPubMed
26.
go back to reference Chaudhry H, Hengerer A, Snyder G. Medical board expectations for physicians recommending marijuana. J Am Med Assoc. 2016;316:577–578.CrossRef Chaudhry H, Hengerer A, Snyder G. Medical board expectations for physicians recommending marijuana. J Am Med Assoc. 2016;316:577–578.CrossRef
Metadata
Title
Profiles of Patients Who Use Marijuana for Inflammatory Bowel Disease
Authors
Ann Marie Kerlin
Millie Long
Michael Kappelman
Christopher Martin
Robert S. Sandler
Publication date
01-06-2018
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 6/2018
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-018-5040-5

Other articles of this Issue 6/2018

Digestive Diseases and Sciences 6/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.